Google
Apple
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
NOVO NORDISK A/S |
Real-time Estimate
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 671.2 DKK | -1.08% | -3.57% | +43.01% | |
| 12-06 | Health Flat as Obesity-Drug Stock Craze Eases -- Health Care Roundup | DJ |
| 12-06 | Berenberg: Novo Nordisk Faces Challenging Momentum Picture as Rivals Bite into Obesity Market | MT |
| Sales 2023 * | 229B 33.04B 2,632B | Sales 2024 * | 278B 40.13B 3,196B | Capitalization | 3,026B 437B 34,789B |
|---|---|---|---|---|---|
| Net income 2023 * | 82.57B 11.92B 949B | Net income 2024 * | 98.26B 14.18B 1,130B | EV / Sales 2023 * | 13,2x |
| Net cash position 2023 * | 12.16B 1.75B 140B | Net cash position 2024 * | 29.1B 4.2B 335B | EV / Sales 2024 * | 10,8x |
| P/E ratio 2023 * | 36,8x | P/E ratio 2024 * | 30,3x | Employees | 61,412 |
| Yield 2023 * | 1,29% | Yield 2024 * | 1,53% | Free-Float | 70.21% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | +0.26% | ||
| 1 week | -1.58% | ||
| Current month | -2.44% | ||
| 1 month | -3.22% | ||
| 3 months | +2.23% | ||
| 6 months | +20.56% | ||
| Current year | +44.67% |
1 week
677.40
699.40
1 month
668.00721.00
Current year
448.25742.20
1 year
441.50742.20
3 years
207.23742.20
5 years
145.90742.20
10 years
94.85742.20
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 57 | 1990 | |
| Director of Finance/CFO | 52 | 1998 | |
| Chief Tech/Sci/R&D Officer | 53 | 1998 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sylvie Grégoire
BRD | Director/Board Member | 62 | 2015 |
Helge Lund
CHM | Chairman | 61 | 2017 |
| Director/Board Member | 64 | 2013 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 25.35% | 670 M€ | +4.22% | ||
| 21.31% | 160 M€ | +14.20% | ||
| 20.86% | 136 M€ | +7.93% | ||
| 18.74% | 644 M€ | +5.38% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 07/12/23 | 670.7 | -1.15% | 457 098 |
| 06/12/23 | 678.5 | -1.25% | 2,221,294 |
| 05/12/23 | 687.1 | -0.74% | 2,380,300 |
| 04/12/23 | 692.2 | -0.93% | 1,606,773 |
| 01/12/23 | 698.7 | +0.46% | 2,585,473 |
Delayed Quote Nasdaq Copenhagen, December 06, 2023 at 03:59 pm
More quotes
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes treatment products (78.9%);
- rare disease treatment products (11.6%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.;
- obesity treatment products (9.5%).
Net sales are distributed geographically as follows: Europe/Middle East/Africa (25%), the United States (47.8%), North America (3.6%), China (9.2%) and other (14.4%).
Sector
Pharmaceuticals
Calendar
31/01/2024
- Q4 2023 Earnings Release
Trading Rating :
Investor Rating :
ESG Refinitiv :
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
678.5DKK
Average target price
685.74DKK
Spread / Average Target
+1.07%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +44.67% | 438 B $ | |
| +61.07% | 530 B $ | |
| -11.34% | 377 B $ | |
| -4.79% | 268 B $ | |
| -9.42% | 258 B $ | |
| +1.56% | 200 B $ | |
| -9.70% | 198 B $ | |
| -43.81% | 163 B $ | |
| +2.55% | 144 B $ | |
| -3.57% | 117 B $ |
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition